IL111872A - Pharmaceutical preparations that include staurosporine as an active ingredient - Google Patents
Pharmaceutical preparations that include staurosporine as an active ingredientInfo
- Publication number
- IL111872A IL111872A IL111872A IL11187294A IL111872A IL 111872 A IL111872 A IL 111872A IL 111872 A IL111872 A IL 111872A IL 11187294 A IL11187294 A IL 11187294A IL 111872 A IL111872 A IL 111872A
- Authority
- IL
- Israel
- Prior art keywords
- active ingredient
- staurosporine
- composition
- composition according
- glyceride
- Prior art date
Links
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 title claims abstract description 30
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 title claims abstract description 30
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 title claims abstract description 30
- 239000004480 active ingredient Substances 0.000 title claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 50
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims abstract description 18
- 125000005456 glyceride group Chemical group 0.000 claims abstract description 17
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 10
- 239000006185 dispersion Substances 0.000 claims abstract description 10
- 229920001515 polyalkylene glycol Polymers 0.000 claims abstract description 10
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 150000002148 esters Chemical class 0.000 claims abstract description 8
- 229920006395 saturated elastomer Polymers 0.000 claims abstract description 8
- 150000004671 saturated fatty acids Chemical class 0.000 claims abstract description 7
- 235000003441 saturated fatty acids Nutrition 0.000 claims abstract description 6
- 239000012736 aqueous medium Substances 0.000 claims abstract description 5
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 7
- 238000002844 melting Methods 0.000 claims description 3
- 230000008018 melting Effects 0.000 claims description 3
- 125000003976 glyceryl group Chemical class [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 2
- 150000002334 glycols Chemical class 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 3
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 3
- 239000004615 ingredient Substances 0.000 claims 1
- 125000005471 saturated fatty acid group Chemical group 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 4
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 239000005639 Lauric acid Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000021314 Palmitic acid Nutrition 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000012768 molten material Substances 0.000 description 2
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 229960002446 octanoic acid Drugs 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 239000006104 solid solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- TUNFSRHWOTWDNC-HKGQFRNVSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCC[14C](O)=O TUNFSRHWOTWDNC-HKGQFRNVSA-N 0.000 description 2
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000006136 alcoholysis reaction Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- -1 benzyl ester Chemical class 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical group 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920001281 polyalkylene Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002525 ultrasonication Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB939325395A GB9325395D0 (en) | 1993-12-11 | 1993-12-11 | Compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL111872A0 IL111872A0 (en) | 1995-06-29 |
| IL111872A true IL111872A (en) | 1998-02-08 |
Family
ID=10746475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL111872A IL111872A (en) | 1993-12-11 | 1994-12-05 | Pharmaceutical preparations that include staurosporine as an active ingredient |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US5736542A (pt) |
| EP (1) | EP0657164B1 (pt) |
| JP (1) | JPH07196512A (pt) |
| KR (1) | KR100366176B1 (pt) |
| AT (1) | ATE185970T1 (pt) |
| AU (1) | AU692801B2 (pt) |
| CA (1) | CA2137764C (pt) |
| DE (1) | DE69421366T2 (pt) |
| DK (1) | DK0657164T3 (pt) |
| ES (1) | ES2140512T3 (pt) |
| GB (1) | GB9325395D0 (pt) |
| GR (1) | GR3032368T3 (pt) |
| IL (1) | IL111872A (pt) |
| NZ (1) | NZ270109A (pt) |
| PH (1) | PH31454A (pt) |
| PT (1) | PT657164E (pt) |
| ZA (1) | ZA949824B (pt) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7795246B2 (en) | 1998-08-06 | 2010-09-14 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US6200968B1 (en) * | 1998-08-06 | 2001-03-13 | Cephalon, Inc. | Particle-forming compositions containing fused pyrrolocarbazoles |
| US6242473B1 (en) * | 1999-01-08 | 2001-06-05 | Maxim Pharmaceuticals, Inc. | Treatment and prevention of reactive oxygen metabolite-mediated cellular damage |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| DE19917990A1 (de) * | 1999-04-20 | 2000-11-02 | Florian Lang | Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk |
| EP1201668A4 (en) | 1999-07-13 | 2003-05-21 | Kyowa Hakko Kogyo Kk | STAUROSPORINE DERIVATIVES |
| DE10042137A1 (de) * | 2000-08-28 | 2002-03-14 | Florian Lang | sgk2 und sgk3 als diagnostische und therapeutische Targets |
| CA2439097C (en) * | 2001-03-26 | 2010-10-12 | Novartis Ag | Pharmaceutical compositions |
| EP1613766A1 (de) * | 2003-03-03 | 2006-01-11 | Florian Physiologisches Institut I Lang | Sgk1 als diagnostisches und therapeutisches target |
| US20040246627A1 (en) * | 2003-06-06 | 2004-12-09 | Durrum Thomas M. | Disc drive pivot bearing assembly |
| AU2004262927B2 (en) | 2003-08-08 | 2008-05-22 | Novartis Ag | Combinations comprising staurosporines |
| AU2004264958B2 (en) | 2003-08-13 | 2010-04-15 | Biocon, Ltd | Micro-particle fatty acid salt solid dosage formulations for therapeutic agents |
| WO2006082448A1 (en) * | 2005-02-07 | 2006-08-10 | Topotarget Uk Limited | Assays for agents with selective cytotoxicty to hdac resistant cell lines |
| US20100168219A1 (en) * | 2008-12-31 | 2010-07-01 | Jonathan Steven Alexander | Chronic inflammation and transplantation |
| US9994585B2 (en) | 2007-12-31 | 2018-06-12 | Aphios Corporation | Transplantation therapies |
| US9034347B2 (en) | 2011-12-19 | 2015-05-19 | Arphios Corporation | Drug delivery system and method for the treatment of neuro-degenerative disease |
| WO2014085494A1 (en) | 2012-11-28 | 2014-06-05 | Aphios Corporation | Combination therapeutics and methods for the treatment of neurodegenerative and other diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60185719A (ja) * | 1984-03-06 | 1985-09-21 | Ajinomoto Co Inc | 抗腫瘍剤 |
| JPH0699311B2 (ja) * | 1986-11-06 | 1994-12-07 | 旭化成工業株式会社 | 抗血管レン縮剤および血管弛緩剤 |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| IL86632A0 (en) * | 1987-06-15 | 1988-11-30 | Ciba Geigy Ag | Derivatives substituted at methyl-amino nitrogen |
| JPH01143877A (ja) * | 1987-11-30 | 1989-06-06 | Asahi Chem Ind Co Ltd | スタウロスポリン誘導体 |
| EP0383919A4 (en) * | 1988-02-04 | 1992-08-05 | Kyowa Hakko Kogyo Co., Ltd. | Staurosporin derivatives |
| JPH0725786A (ja) * | 1990-05-16 | 1995-01-27 | Univ Rockefeller | アルツハイマー病を伴うアミロイドーシスの治療 |
| JPH06501024A (ja) * | 1991-03-29 | 1994-01-27 | アメリカ合衆国 | 皮膚腫瘍形成を予防し、存在する腫瘍の後退の原因になるための医薬組成物と方法 |
| JPH0597708A (ja) * | 1991-10-02 | 1993-04-20 | Lion Corp | 歯周病治療剤 |
| WO1993007153A1 (en) * | 1991-10-10 | 1993-04-15 | Schering Corporation | 4'-(n-substituted-n-oxide)staurosporine derivatives |
| JPH05247055A (ja) * | 1992-03-03 | 1993-09-24 | Meiji Seika Kaisha Ltd | スタウロスポリン誘導体及びそれを含有する抗腫瘍効果増強剤 |
-
1993
- 1993-12-11 GB GB939325395A patent/GB9325395D0/en active Pending
-
1994
- 1994-11-18 PH PH49409A patent/PH31454A/en unknown
- 1994-11-22 US US08/343,404 patent/US5736542A/en not_active Expired - Fee Related
- 1994-12-02 DK DK94308954T patent/DK0657164T3/da active
- 1994-12-02 ES ES94308954T patent/ES2140512T3/es not_active Expired - Lifetime
- 1994-12-02 PT PT94308954T patent/PT657164E/pt unknown
- 1994-12-02 EP EP94308954A patent/EP0657164B1/en not_active Expired - Lifetime
- 1994-12-02 AT AT94308954T patent/ATE185970T1/de active
- 1994-12-02 DE DE69421366T patent/DE69421366T2/de not_active Expired - Lifetime
- 1994-12-05 IL IL111872A patent/IL111872A/en not_active IP Right Cessation
- 1994-12-08 AU AU80308/94A patent/AU692801B2/en not_active Ceased
- 1994-12-09 KR KR1019940033397A patent/KR100366176B1/ko not_active IP Right Cessation
- 1994-12-09 NZ NZ270109A patent/NZ270109A/en not_active IP Right Cessation
- 1994-12-09 ZA ZA949824A patent/ZA949824B/xx unknown
- 1994-12-09 CA CA002137764A patent/CA2137764C/en not_active Expired - Fee Related
- 1994-12-12 JP JP6307534A patent/JPH07196512A/ja active Pending
-
2000
- 2000-01-14 GR GR20000400066T patent/GR3032368T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2137764C (en) | 2006-02-07 |
| PT657164E (pt) | 2000-04-28 |
| KR960021018A (ko) | 1996-07-18 |
| KR100366176B1 (ko) | 2003-03-03 |
| AU8030894A (en) | 1995-06-22 |
| CA2137764A1 (en) | 1995-06-12 |
| DE69421366D1 (de) | 1999-12-02 |
| DE69421366T2 (de) | 2000-03-23 |
| DK0657164T3 (da) | 2000-04-17 |
| PH31454A (en) | 1998-11-03 |
| EP0657164B1 (en) | 1999-10-27 |
| GB9325395D0 (en) | 1994-02-16 |
| AU692801B2 (en) | 1998-06-18 |
| ES2140512T3 (es) | 2000-03-01 |
| NZ270109A (en) | 1996-11-26 |
| ATE185970T1 (de) | 1999-11-15 |
| EP0657164A1 (en) | 1995-06-14 |
| JPH07196512A (ja) | 1995-08-01 |
| ZA949824B (en) | 1995-07-13 |
| IL111872A0 (en) | 1995-06-29 |
| GR3032368T3 (en) | 2000-04-27 |
| US5736542A (en) | 1998-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0657164B1 (en) | Pharmaceutical compositions containing staurosporine derivatives and a polyalkylene glycol glyceride | |
| KR102685325B1 (ko) | 칸나비노이드를 포함하는 변형 방출형 조성물 | |
| CN111787910B (zh) | 包含大麻素和泊洛沙姆的口服药物制剂 | |
| CA3028580C (en) | Cannabinoid formulations | |
| TWI490216B (zh) | 用作ｃ型肝炎病毒蛋白酶抑制劑之醫藥組合物 | |
| CA3087122A1 (en) | Pharmaceutical composition comprising a cannabinoid | |
| NL9000428A (nl) | Farmaceutische samenstellingen. | |
| JP2020533297A (ja) | 医薬組成物 | |
| JP2003503339A (ja) | 抗癌剤を含有する自己乳化システム | |
| CZ291237B6 (cs) | Farmaceutický přípravek pro orální podání obsahující cyklosporin A | |
| MXPA04008151A (es) | Capsulas de envoltura dura que contienen ibuprofeno. | |
| CN111356450A (zh) | Pde5抑制剂的液体填充制剂 | |
| RU2823982C1 (ru) | Фармацевтическая композиция на основе ментилового эфира индометацина в виде твердой самоэмульгирующейся системы | |
| US20190247308A1 (en) | Stable liquid formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXP | Patent expired |